Identification of Blood Biomarkers Associated with Cardiac Remodeling after Myocardial Infarction

Identification of Blood Biomarkers Associated with Cardiac Remodeling after Myocardial Infarction - Identification of Blood Biomarkers Associated with Cardiac Remodeling after Myocardial Infarction

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045598

Enrollment

200

Registered

2021-09-29

Start date

2021-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Persons who have given written consent to participate in the research. 2. Males and females aged 20 years or older at the time of obtaining consent 3. Patients who have been diagnosed with myocardial infarction at a research participating institutions

Exclusion criteria

Exclusion criteria: 1. Hemodialysis cases 2. Patients with cancer 3. Patients with blood disorders

Design outcomes

Primary

Measure	Time frame
Patients who have suffered a myocardial infarction and are being treated at the study institutions will be recruited as study subjects at the time of outpatient or inpatient care. An additional 10 ml of blood will be collected for research purposes when blood samples are taken for usual medical treatment, and biomarkers will be measured (plasma proteome analysis using SomaLogic's SOMAscan or ELISA analysis of target proteins). At the same time, clinical information will be registered using the EDC system after anonymization. These specimen and information collection will be collected in the acute phase immediately before or after hospitalization, in the subacute phase before discharge, and in the chronic phase approximately six months to one year later. As a result, the primary endpoint of the study will be to validate the efficacy of blood biomarkers as predictors of myocardial remodeling after myocardial infarction.	—

Measure

Time frame

Patients who have suffered a myocardial infarction and are being treated at the study institutions will be recruited as study subjects at the time of outpatient or inpatient care. An additional 10 ml of blood will be collected for research purposes when blood samples are taken for usual medical treatment, and biomarkers will be measured (plasma proteome analysis using SomaLogic's SOMAscan or ELISA analysis of target proteins). At the same time, clinical information will be registered using the EDC system after anonymization. These specimen and information collection will be collected in the acute phase immediately before or after hospitalization, in the subacute phase before discharge, and in the chronic phase approximately six months to one year later. As a result, the primary endpoint of the study will be to validate the efficacy of blood biomarkers as predictors of myocardial remodeling after myocardial infarction.

—

Countries

Japan

Contacts

Public ContactSeitaro Nomura

Graduate School of Medicine and Faculty of Medicine, The University of Tokyo Department of Therapeutic Strategy for Heart Failure

seitaro_n@msn.com03-3815-5411

Outcome results